Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma

Peer Review reports

Original Submission
21 Dec 2021	Submitted	Original manuscript
1 Jun 2022	Reviewed	Reviewer Report
12 Jul 2022	Reviewed	Reviewer Report
15 Aug 2022	Author responded	Author comments - Miki Takenaka Sato
Resubmission - Version 2
15 Aug 2022	Submitted	Manuscript version 2
25 Aug 2022	Reviewed	Reviewer Report
21 Sep 2022	Reviewed	Reviewer Report
11 Nov 2022	Author responded	Author comments - Miki Takenaka Sato
Resubmission - Version 3
11 Nov 2022	Submitted	Manuscript version 3
Publishing
14 Nov 2022	Editorially accepted
24 Nov 2022	Article published	10.1186/s12885-022-10316-w

Back to article page